Routine measurement of cardiac biomarkers can help reclassify pre heart failure stages
USA: A recent study has suggested that cardiac biomarkers incorporation into HF (heart failure) assessment may better pinpoint patients otherwise missed by older disease.Researchers have found in ARIC study that inclusion of cardiac biomarkers into HF assessment may better pinpoint patients who otherwise would have been missed by older disease definitions. One in five asymptomatic elderly individuals in the study were reclassified from Stage A to Stage B through the inclusion of natriuretic peptide or cardiac troponin elevations.
"The routine biomarkers measurement can help identify people at higher risk of heart failure who may benefit most from HF prevention efforts.
The study has been published online in JACC: Heart Failure.
The findings align with recommendations from the most recent heart failure guidelines from the ACC (American College of Cardiology), the AHA (American Heart Association) and the HFSA (Heart Failure Society of America). The guidelines revised the HF staging system, emphasizing early detection of stage A (at risk) and stage B or pre-HF (asymptomatic with structural evidence of heart dysfunction). The guidelines recommend blood tests for cardiac troponin and natriuretic peptides in Stage B assessment in keeping with a proposed new universal HF definition.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.